Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT07527260Not yet recruiting
Randomised, open-label trial in allergic rhinitis (AR) and Adenotonsillar hypertrophy (ATH) (3 arms), sponsored by Tongji Hospital. Primary endpoints: Symptom scores at 6 months and Allergen-Specific IgE Levels in Nasal Cavity at 6 months. Planned start Apr 2026; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT07527260.